Skip to main content

4 Result(s)

within Hazel Squires Remove this filter Medicine & Public Health Remove this filter Pharmacoeconomics and Health Outcomes Remove this filter

and

  1. Article

    Open Access

    Systematic review and critical methodological appraisal of community-based falls prevention economic models

    Falls impose significant health and economic burdens on community-dwelling older persons. Decision modelling can inform commissioning of alternative falls prevention strategies. Several methodological challeng...

    Joseph Kwon, Hazel Squires, Matthew Franklin… in Cost Effectiveness and Resource Allocation (2022)

    Download PDF (1106 KB) View Article

  2. No Access

    Article

    Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme) of pembrolizumab (Keytruda®) to submit evidenc...

    Shijie Ren, Hazel Squires, Emma Hock, Eva Kaltenthaler, Andrew Rawdin… in PharmacoEconomics (2019)

  3. No Access

    Article

    Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer of pertuzumab (Perjeta®; Roche Products Limited) to submit evidence of its clinic...

    Hazel Squires, Abdullah Pandor, Praveen Thokala, John W. Stevens… in PharmacoEconomics (2018)

  4. No Access

    Article

    Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    The National Institute for Health and Care Excellence (NICE) invited the manufacturer of trastuzumab emtansine (T-DM1) (Kadcyla®; Roche) to submit evidence of its clinical and cost-effectiveness for treating huma...

    Hazel Squires, Matt Stevenson, Emma Simpson, Rebecca Harvey… in PharmacoEconomics (2016)